Technical Analysis for AKBA - Akebia Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 2.7884 -1.12% -0.03
AKBA closed up 0.71 percent on Monday, September 21, 2020, on 2.35 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical AKBA trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction -1.12%
Wide Bands Range Expansion -1.12%
Oversold Stochastic Weakness -1.12%
1,2,3 Retracement Bearish Bearish Swing Setup -0.41%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.41%
Volume Surge Other -0.41%
Narrow Range Bar Range Contraction -0.41%
Inside Day Range Contraction -0.41%
Wide Bands Range Expansion -0.41%
Oversold Stochastic Weakness -0.41%
Older End-of-Day Gignals for AKBA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % 36 minutes ago
Down 1% 36 minutes ago
1.5x Volume Pace about 1 hour ago
Up 2% about 1 hour ago
Up 1% about 1 hour ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Biopharmaceutical Dialysis Chronic Kidney Disease Anemia Kidney Kidney Disease Hypoxia Inducible Factors

Is AKBA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.71
52 Week Low 2.46
Average Volume 5,052,319
200-Day Moving Average 8.96
50-Day Moving Average 9.09
20-Day Moving Average 5.66
10-Day Moving Average 2.70
Average True Range 0.60
ADX 49.99
+DI 10.13
-DI 48.14
Chandelier Exit (Long, 3 ATRs ) 9.45
Chandelier Exit (Short, 3 ATRs ) 4.27
Upper Bollinger Band 12.92
Lower Bollinger Band -1.61
Percent B (%b) 0.3
BandWidth 256.83
MACD Line -2.11
MACD Signal Line -2.03
MACD Histogram -0.0791
Fundamentals Value
Market Cap 51.61 Million
Num Shares 18.3 Million
EPS -3.60
Price-to-Earnings (P/E) Ratio -0.78
Price-to-Sales 6.10
Price-to-Book 12.65
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.15
Resistance 3 (R3) 3.13 3.01 3.10
Resistance 2 (R2) 3.01 2.92 3.02 3.08
Resistance 1 (R1) 2.91 2.87 2.96 2.93 3.06
Pivot Point 2.79 2.79 2.81 2.80 2.79
Support 1 (S1) 2.69 2.70 2.74 2.71 2.58
Support 2 (S2) 2.57 2.65 2.58 2.56
Support 3 (S3) 2.47 2.57 2.55
Support 4 (S4) 2.49